Skip to content

Clinical trials

Esophageal Squamous Cell Carcinoma trials in China with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Esophageal Squamous Cell Carcinoma Status: Unknown status Country / region: China Clear all

109 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20102
20114
20121
20134
20146
20153
20164
20175
20185
201916
202013
202112
202220
202312
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status109

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University10
Peking University8
Sun Yat-sen University8
The First Affiliated Hospital of Zhengzhou University8
Sichuan Cancer Hospital and Research Institute6
The First Affiliated Hospital of Henan University of Science and Technology5
Chinese Academy of Medical Sciences4
Zhejiang Cancer Hospital4
Guangdong Provincial People's Hospital3
Shanghai Chest Hospital3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Esophageal Squamous Cell Carcinoma109
Esophageal Neoplasms19
Esophageal Diseases3
Carcinoma, Squamous Cell2
Biliary Tract Neoplasms1
Carcinoma1
Carcinoma, Non-Small-Cell Lung1
Colorectal Neoplasms1
Deglutition Disorders1
Hypersensitivity1

Trials

Showing 1 to 25 of 109. Each trial links to its page on Pharma Observatory.

9 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.